PMID- 32016810
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20211204
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 26
IP  - 1
DP  - 2020 Jan
TI  - mTOR in Lung Neoplasms.
PG  - 35-48
LID - 10.1007/s12253-020-00796-1 [doi]
AB  - With the discovery of rapamycin 45 years ago, studies in the mechanistic target 
      of rapamycin (mTOR) field started 2 decades before the identification of the mTOR 
      kinase. Over the years, studies revealed that the mTOR signaling is a master 
      regulator of homeostasis and integrates a variety of environmental signals to 
      regulate cell growth, proliferation, and metabolism. Deregulation of mTOR 
      signaling, particularly hyperactivation, frequently occurs in human tumors. 
      Recent advances in molecular profiling have identified mutations or amplification 
      of certain genes coding proteins involved in the mTOR pathway (eg, PIK3CA, PTEN, 
      STK11, and RICTOR) as the most common reasons contributing to mTOR 
      hyperactivation. These genetic alterations of the mTOR pathway are frequently 
      observed in lung neoplasms and may serve as a target for personalized therapy. 
      mTOR inhibitor monotherapy has met limited clinical success so far; however, 
      rational drug combinations are promising to improve efficacy and overcome 
      acquired resistance. A better understanding of mTOR signaling may have the 
      potential to help translation of mTOR pathway inhibitors into the clinical 
      setting.
FAU - Krencz, Ildiko
AU  - Krencz I
AD  - 1st Department of Pathology and Experimental Cancer Research, Semmelweis 
      University, Budapest, Hungary.
FAU - Sebestyen, Anna
AU  - Sebestyen A
AD  - 1st Department of Pathology and Experimental Cancer Research, Semmelweis 
      University, Budapest, Hungary.
FAU - Khoor, Andras
AU  - Khoor A
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo 
      Road, Jacksonville, FL, 32224, USA. Khoor.Andras@mayo.edu.
LA  - eng
GR  - ED_17-1-2017-0009/Nemzeti Kutatasi, Fejlesztesi es Innovacios Alap/
GR  - NKFI-FK-128404/Nemzeti Kutatasi Fejlesztesi es Innovacios Hivatal/
GR  - NVKP_16-1-2016-0004/Nemzeti Kutatasi Fejlesztesi es Innovacios Hivatal/
PT  - Journal Article
PT  - Review
DEP - 20200203
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Biomarkers, Tumor/antagonists & inhibitors/genetics/metabolism
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*metabolism/pathology
MH  - Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors/metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/antagonists & inhibitors/metabolism
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Signal Transduction/drug effects/genetics
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
OTO - NOTNLM
OT  - Lung neoplasms
OT  - mTOR inhibitors
OT  - mTOR signaling
OT  - mTORC1
OT  - mTORC2
EDAT- 2020/02/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - 10.1007/s12253-020-00796-1 [pii]
AID - 10.1007/s12253-020-00796-1 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2020 Jan;26(1):35-48. doi: 10.1007/s12253-020-00796-1. Epub 
      2020 Feb 3.